Dergiler / Eurasian Journal of Medical Investigation / 2019 / Cilt: 3 - Sayı: 1

Management of Neonatal Supraventricular Tachycardias; A Single Center Experience

Sayfa
46–53
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Amiodarone and/or esmolol for acute treatment was used in 39.1%.Propranolol, digoxin, amiodarone, propafenone and flecainide were the drugs used for monotherapy or combinationtherapies.Conclusion: In patients with initially unresponsive to standard dose of adenosine and under acute treatment withamiodarone and/or emolol continuous infusion, higher doses of adenosine (300-500 μg/gr/kg) is very effective.Amiodarone alone and in combination with flecainide seems safe and effective.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: Emergent treatment of neonatal supraventricular tachycardia (SVT) is very crucial because it may lead tolife threating conditions.
📊
Temel Bulgular & Veri:The aim of this study is to evaluate the neonatal SVTs.Methods: Neonates, who were diagnosed with SVT between December 2014 and May 2018, were analyzed.
💡
Sonuç & Katkı:Amiodarone and/or esmolol for acute treatment was used in 39.1%.Propranolol, digoxin, amiodarone, propafenone and flecainide were the drugs used for monotherapy or combinationtherapies.Conclusion: In patients with initially unresponsive to standard dose of adenosine and under acute treatment withamiodarone and/or emolol continuous infusion, higher doses of adenosine (300-500 μg/gr/kg) is very effective.Amiodarone alone and in combination with flecainide seems safe and effective.
🔬Tür:Araştırma Makalesi
📍Kapsam:2014 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: Emergent treatment of neonatal supraventricular tachycardia (SVT) is very crucial because it may lead tolife threating conditions. The aim of this study is to evaluate the neonatal SVTs.Methods: Neonates, who were diagnosed with SVT between December 2014 and May 2018, were analyzed. Clinicalfindings, electrocardiogram (ECG) and echocardiography findings, 24-hour Holter ECG recordings and medicationswere evaluated.Results: 46 over 1932 newborns were diagnosed with SVT. 76% of patients were common SVT with narrow QRS andshort RP, 13% with Wolff-Parkinson-White syndrome, 4.3% with multifocal atrial tachycardia, 4.3% with atrial flutter,2.1% with permanent reciprocating junctional tachycardia. Adenosine terminated SVT in 84.4% of the cases. Synchronizedcardioversion was performed in 10.8% cases. Amiodarone and/or esmolol for acute treatment was used in 39.1%.Propranolol, digoxin, amiodarone, propafenone and flecainide were the drugs used for monotherapy or combinationtherapies.Conclusion: In patients with initially unresponsive to standard dose of adenosine and under acute treatment withamiodarone and/or emolol continuous infusion, higher doses of adenosine (300-500 μg/gr/kg) is very effective.Amiodarone alone and in combination with flecainide seems safe and effective.

🔖

Bu Makaleye Atıf Yap

EPCACAN, S. (2022). Management of Neonatal Supraventricular Tachycardias; A Single Center Experience. Eurasian Journal of Medical Investigation, Cilt: 3 - Sayı: 1, 46–53. https://ajindex.com/articles/508710

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (17)

  1. Kundak AA, Dilli D, Karagol B, Karadag N, Zenciroglu A, Okumus N, et al. Non benign neonatal arrhythmias observed in a tertiary neonatal intensive care unit. Indian J Pediatr 2013;80:555–9
  2. Ban JE. Neonatal arrhythmias: diagnosis, treatment, and clinical outcome. Korean J Pediatr 2017;60:344–52
  3. Southall DP, Richards J, Mitchell P, Brown DJ, Johnston PG, Shinebourne EA. Study of cardiac rhythm in healthy newborn infants. Br Heart J 1980;43:14–20
  4. Badrawi N, Hegazy RA, Tokovic E, Lotfy W, Mahmoud F, Aly H. Arrhythmia in the neonatal intensive care unit. Pediatr Cardiol 2009;30:325–30
  5. Jaeggi E, Ohman A. Fetal and Neonatal Arrhythmias. Clin Perinatol 2016;43:99–112
  6. Moak JP. Supraventricular tachycardia in the neonate and infant. Prog Pediatr Cardiol 2000;11:25–38
  7. Fox DJ, Tischenko A, Krahn AD, Skanes AC, Gula LJ, Yee RK, et al. Supraventricular tachycardia: diagnosis and management. Mayo Clin Proc 2008;83:1400–11
  8. Bolat F US, Cömert S, Dindar A, Bülbül A, Nuhoğlu A. Yenidoğanda supraventiküler taşikardi vakası: Güncel tedavi yaklaşımı. Çocuk Dergisi 2010;10:51–4
  9. O'Rourke SF, Sauvage A, Evans PA. Paroxysmal supraventricular tachycardia: improving diagnosis and management within the accident and emergency department. Emerg Med J 2004;21:495–7
  10. Chu PY, Hill KD, Clark RH, Smith PB, Hornik CP. Treatment of supraventricular tachycardia in infants: Analysis of a large multicenter database. Early Hum Dev 2015;91:345–50
  11. Wong KK, Potts JE, Etheridge SP, Sanatani S. Medications used to manage supraventricular tachycardia in the infant a North American survey. Pediatr Cardiol 2006;27:199–203
  12. Garson A, Jr., Gillette PC, McNamara DG. Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow-up in 217 patients. J Pediatr 1981;98:875–82
  13. Nagehan Katipoğlu ŞÇ, Özgür Olukman, Kıymet Çelik, Timur Meşe. Yenidoğan Döneminde Supraventriküler Taşikardi: Tanı, Tedavi ve Prognoza Etki Eden Faktörler Çocuk Dergisi 2017;17:163–8
  14. Binnetoglu FK, Babaoglu K, Turker G, Altun G. Diagnosis, treatment and follow up of neonatal arrhythmias. Cardiovasc J Afr 2014;25:58–62
  15. Gilljam T, Jaeggi E, Gow RM. Neonatal supraventricular tachycardia: outcomes over a 27-year period at a single institution. Acta Paediatr 2008;97:1035–9
  16. Harinder R. Singh SG, Michael L. Epstein, Thomas L’Ecuyer. Neonatal Supraventricular Tachycardia (SVT). NeoReviews 2005;6:339–50
  17. Satar M NN, Özbarlas N, Yapıcıoğ